基石药业-B宣布舒格利单抗(择捷美?)GEMSTONE-303研究数据在JAMA发表

格隆汇
25 Feb

格隆汇2月25日丨基石药业-B(02616.HK)宣布,舒格利单抗(择捷美?)GEMSTONE-303研究结果在国际顶级医学期刊《美国医学会杂志》(JAMA)主刊正式发表。关键亮点:? 舒格利单抗是全球首个获批用于胃/胃食管结合部(G/GEJ)腺癌的PD-L1单抗,GEMSTONE-303研究结果为其联合化疗成为PD-L1综合阳性评分(CPS)≥5患者中新的一线标准疗法提供了有力支撑。? 舒格利...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10